CA3266315A1 - Nerve Growth Factor (NGF) for the Treatment of Spasticity - Google Patents

Nerve Growth Factor (NGF) for the Treatment of Spasticity

Info

Publication number
CA3266315A1
CA3266315A1 CA3266315A CA3266315A CA3266315A1 CA 3266315 A1 CA3266315 A1 CA 3266315A1 CA 3266315 A CA3266315 A CA 3266315A CA 3266315 A CA3266315 A CA 3266315A CA 3266315 A1 CA3266315 A1 CA 3266315A1
Authority
CA
Canada
Prior art keywords
spasticity
ngf
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3266315A
Other languages
English (en)
French (fr)
Inventor
Marcello Allegretti
Andrea Aramini
Laura Brandolini
Franca CATTANI
Flavio Mantelli
Original Assignee
Dompe Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Farmaceutici SpA filed Critical Dompe Farmaceutici SpA
Publication of CA3266315A1 publication Critical patent/CA3266315A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA3266315A 2022-09-23 2023-09-25 Nerve Growth Factor (NGF) for the Treatment of Spasticity Pending CA3266315A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22197562.6 2022-09-23
EP22197562.6A EP4342485A1 (en) 2022-09-23 2022-09-23 Ngf for the treatment of spasticity
PCT/EP2023/076387 WO2024062135A1 (en) 2022-09-23 2023-09-25 Ngf for the treatment of spasticity

Publications (1)

Publication Number Publication Date
CA3266315A1 true CA3266315A1 (en) 2024-03-28

Family

ID=83438536

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3266315A Pending CA3266315A1 (en) 2022-09-23 2023-09-25 Nerve Growth Factor (NGF) for the Treatment of Spasticity

Country Status (7)

Country Link
EP (2) EP4342485A1 (https=)
JP (1) JP2025532676A (https=)
CN (1) CN120239610A (https=)
AU (1) AU2023345675A1 (https=)
CA (1) CA3266315A1 (https=)
IL (1) IL319010A (https=)
WO (1) WO2024062135A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026022244A1 (en) 2024-07-23 2026-01-29 Chiesi Farmaceutici S.P.A. A polypeptide for use in the therapeutic management of acute ischaemic stroke

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2213861T3 (es) 1998-10-09 2004-09-01 Scil Proteins Gmbh Procedimiento de obtencion de ngf-beta activa.
CN1112215C (zh) * 1999-12-28 2003-06-25 潘晓东 神经生长因子在治疗有机溶剂中毒性周围神经病中的用途
CN104203264B (zh) 2011-12-19 2018-08-28 瓦克化学有限公司 新型proNGF突变体及其在生产β-NGF中的用途
WO2017157325A1 (zh) * 2016-03-18 2017-09-21 舒泰神（北京）生物制药股份有限公司 神经生长因子融合蛋白、制备方法及其用途
IT201600112420A1 (it) * 2016-11-08 2018-05-08 Univ Cattolica Del Sacro Cuore Nuova formulazione per via intranasale
MA52351A (fr) 2018-04-27 2021-05-26 Chiesi Farm Spa Production du facteur de croissance nerveuse (ngf) et de mutéines de celui-ci
HRP20241431T1 (hr) * 2019-09-17 2024-12-20 Chiesi Farmaceutici S.P.A. Mutant ngf za upotrebu u liječenju ili prevenciji oftalmoloških poremećaja
CN114829384B (zh) * 2020-11-19 2023-12-12 舒泰神（北京）生物制药股份有限公司 长效神经生长因子多肽及其用途

Also Published As

Publication number Publication date
WO2024062135A1 (en) 2024-03-28
CN120239610A (zh) 2025-07-01
EP4342485A1 (en) 2024-03-27
IL319010A (en) 2025-04-01
AU2023345675A1 (en) 2025-03-06
EP4590324A1 (en) 2025-07-30
JP2025532676A (ja) 2025-10-01

Similar Documents

Publication Publication Date Title
EP4139280A4 (en) LINKS TO TREATMENT OF SARS
EP4255401A4 (en) COMPOUNDS FOR TREATING SARS
CA3266315A1 (en) Nerve Growth Factor (NGF) for the Treatment of Spasticity
EP4245100A4 (en) SUBSTRATE PROCESSING SYSTEM
EP4362963A4 (en) YEAST FOR THE TREATMENT OF INFLAMMATION
AU2024396398A1 (en) Therapy for the treatment of multiple myeloma
HK40128655A (zh) 用於治疗抑郁症的方法
CA3266806A1 (en) METHODS FOR TREATING DEPRESSION
AU2020904747A0 (en) System for treatment of substrates
HK40108886A (en) Aav for the gene therapy of wet-amd
AU2022299062C1 (en) Environmental-friendly process for the treatment of wastewater
CA3291458A1 (en) Therapy
CA3271207A1 (en) Therapy
CA3264674A1 (en) TREATMENT OF FASCIOLOSIS
CA3305498A1 (en) Methods for the treatment of multiple myeloma
HK40085033A (en) Tafoxiparin for the treatment of preeclampsia
CA3308179A1 (en) Londamocitinib for the treatment of asthma
HK40107501A (en) Gene therapy for treating beta-hemoglobinopathies
HK40081993A (en) Compounds for the treatment of covid-19
CA3290995A1 (en) Gene therapy
CA3286101A1 (en) Gene therapy
CA3264521A1 (en) GENE THERAPY
CA3275952A1 (en) Nootkatone for the treatment of pruritus
AU2023901913A0 (en) Processes
CA3273488A1 (en) Gene therapy for frontotemporal dementia

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20250224

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20250516

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250516

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250527

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250527

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250527

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250528

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250603

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20250603